Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
J. Jean Cui
Observed names:
J. Cui,
J. Jean Cui.,
J.J. Cui,
Jianzhao Cui
Observed institutions:
Pfizer (United States),
Huazhong Agricultural University,
Tibet Academy of Agricultural and Animal Husbandry Sciences,
First Hospital of Jilin University,
Ministry of Agriculture and Rural Affairs
ORCID:
0009-0005-6287-1455
Observed ORCID:
0009-0005-6287-1455
OpenAlex ID:
A5045957422
Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress
2013
·
J. Jean Cui
·
Journal of Medicinal Chemistry
·
210
A New Challenging and Promising Era of Tyrosine Kinase Inhibitors
2014
·
J. Jean Cui
·
ACS Medicinal Chemistry Letters
·
36
Case History
2013
·
J. Jean Cui
, Michele McTigue
, et al.
·
Annual reports in medicinal chemistry
·
23
Abstract 2132: The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors
2016
·
Dayong Zhai
, Wei Deng
, et al.
·
Cancer Research
·
12
Abstract 3161: TPX-0005, an ALK/ROS1/TRK inhibitor, overcomes multiple resistance mechanisms by targeting SRC/FAK signaling
2017
·
Dayong Zhai
, Wei Deng
, et al.
·
Cancer Research
·
8
P3.02a-009 TPX-0005: A Multi-Faceted Approach to Overcoming Clinical Resistances from Current ALK or ROS1 Inhibitor Treatment in Lung Cancer
2017
·
J. Jean Cui
, Dayong Zhai
, et al.
·
Journal of Thoracic Oncology
·
7
PDF
Abstract 2133: Ending the endless acquired tyrosine kinase resistance mutations — Design of TPX-0005, a multi-target ALK/ROS1/TRK inhibitor with broad spectrum activity against wild-type and mutants including ALK G1202R, ROS1 G2032R and TRKA G595R
2016
·
J. Jean Cui
, Evan Rogers
, et al.
·
Cancer Research
·
7
Abstract 1325: TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC inhibits tumor growth by promoting anti-tumor immune responses
2019
·
Wei Deng
, Dayong Zhai
, et al.
·
Cancer Research
·
6
Multi-omics analysis of the mechanism of alfalfa and wheat-induced rumen flatulence in Xizang sheep
2025
·
Jing Wu
, Xiaoming Zhang
, et al.
·
Microbiology Spectrum
·
4
Abstract B186: TPX-0005, a polypharmacology inhibitor, overcomes ALK treatment resistance from acquired mutations, bypass signaling, and EMT
2018
·
Dayong Zhai
, Wei Deng
, et al.
·
Molecular Cancer Therapeutics
·
4
Abstract B185: TPX-0005, a supreme ROS1 inhibitor, overcomes crizotinib-resistant ROS1 mutations including solvent front mutation G2032R and gatekeeper mutation L2026M
2018
·
J. Jean Cui
, Dayong Zhai
, et al.
·
Molecular Cancer Therapeutics
·
3
First-in-human trial of BH-30643, a novel macrocyclic, non-covalent, mutant-selective OMNI-EGFR inhibitor, in EGFR -mutant ( EGFR m) NSCLC.
2026
·
Xiuning Le
, Alexander I. Spira
, et al.
·
Journal of Clinical Oncology
·
2
PDF
Abstract 5944: Discovery of BH-30236: A novel macrocyclic CLK inhibitor targeting alternative splicing in cancers
2024
·
J. Jean Cui
, Ping Jiang
, et al.
·
Cancer Research
·
2
P2.02.29 CXCR2 Inhibitor Plus KRAS G12C Inhibitor Remodels Immunosuppressive Tumor Microenvironment in KRAS G12C-Mutant NSCLC?
2025
·
D. He
, N. Chen
, et al.
·
Journal of Thoracic Oncology
·
1
BH-30236, a Novel Macrocyclic Clk Inhibitor Modulating Aberrant RNA Splicing, Demonstrates Potent Anti-Cancer Activity Against Myeloid Malignancies
2024
·
Wei Deng
, Ping Jiang
, et al.
·
Blood
·
1
Abstract 617: BH-30236, a novel macrocyclic CLK inhibitor modulating RNA splicing, demonstrates potent inhibition of cancer cell growth in a broad panel of cancer cell lines
2024
·
Ping Jiang
, Danan Li
, et al.
·
Cancer Research
·
1
P76.35 Genomic Characteristics and Prognosis of Concomitant with EGFR Copy Numbers Variations in EGFR Mutated Lung Cancer Patients
2021
·
J. Cui
, X. Ai
, et al.
·
Journal of Thoracic Oncology
·
1
PDF
Abstract 1958: Repotrectinib increases effectiveness of KRAS-G12C inhibitors in KRAS-G12C mutant cancer models via simultaneous SRC/FAK/JAK2 inhibition
2020
·
J. Jean Cui
, Dayong Zhai
, et al.
·
Cancer Research
·
1
Abstract 1321: TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC for treatment of cancers with abnormal HGF/MET signaling
2019
·
Dayong Zhai
, Evan Rogers
, et al.
·
Experimental and Molecular Therapeutics
·
1
Abstract 5872: CLK inhibitor BH-30236 synergizes with venetoclax in anti-leukemia activity via splicing modulation in preclinical AML and CLL models
2026
·
Wei Deng
, Ping Jiang
, et al.
·
Cancer Research
A phase 1/1b open-label, dose escalation, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available clk inhibitor, BH-30236, in adults with R/R AML or HR-MDS
2025
·
Eytan Stein
, Alice Mims
, et al.
·
Blood
PDF
A phase 1/2 open-label, multicenter, first-in-human study of the safety, tolerability, pharmacokinetics, and antitumor activity of BH-30643 in adult subjects with locally advanced or metastatic NSCLC harboring EGFR and/or HER2 mutations (SOLARA).
2025
·
Xiuning Le
, Alexander I. Spira
, et al.
·
Journal of Clinical Oncology
PDF
Multi-omics analysis of the mechanism of alfalfa and wheat-induced rumen flatulence in Xizang sheep
2024
·
Tianzeng Song
, Jing Wu
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
Liver Transcriptome Analysis Reveals the Mechanisms of Metabolic Adaptation of Xizang Sheep to Seasonal Changes
2024
·
Jianzhao Cui
, Junru Pan
, et al.
·
Metabolites
PDF
A Phase 1/1b Open-Label, Dose Escalation, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Leukemic Activity of the Orally Available CDC-like Kinase Inhibitor, BH-30236, in Adults with R/R AML or HR-MDS
2024
·
Eytan M. Stein
, Leora Boussi
, et al.
·
Blood
PDF
Show more works
View as search
Works count:
29
Citation count:
330
H-index:
7
I10-index:
4
Year
Topic
Type
